NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants Alphabet, Amazon, Apple and Facebook all saw gains of over 2 percent on Tuesday. The Dow Jones Industrial Average jumped 0.65 percent to settle at 24,065.59, while the S&P 500 hiked 1.07 percent to close at 2,610.30. The Nasdaq advanced 1.71 percent to settle at 7,023.83.
"Investors will likely view this above-Street estimate increase quite positively, bolstering confidence in subscriber trends, pace of revenue growth and ability to achieve guidance for margin gains," said Credit Suisse analyst, Doug Mitchelson.
The Market Edge Initiates Coverage on:
Amicus Therapeutics, Inc.
Sage Therapeutics, Inc.
Amicus Therapeutics' stock jumped 5.36% Tuesday, to close the day at $11.99. The stock recorded a trading volume of 2,376,565 shares, which was below its three months average volume of 2,678,012 shares. In the last year, Amicus Therapeutics' shares have traded in a range of 8.27 - 17.62. The share price has gained 44.98% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $10.36 is below its 200-day moving average of $12.41. Shares of Amicus Therapeutics have gained roughly 14.08 percent in the past month and are up 25.16 percent year-to-date.
Access The Market Edge's Amicus Therapeutics, Inc. Research Report:
On Tuesday, shares of Sage Therapeutics recorded a trading volume of 763,636 shares, which was above the three months average volume of 560,341 shares. The stock ended the day 3.9% higher at $131.94. The share price has fallen 32.67% from its 52 week high with a 52 week trading range of 79.88 - 195.97. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $105.31 is below its 200-day moving average of $133.38. Shares of Sage Therapeutics have gained roughly 29.37 percent in the past month and are up 37.74 percent year-to-date.
Access The Market Edge's Sage Therapeutics, Inc. Research Report:
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered
For any questions, inquiries, or comments reach out to us directly at:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute